UNITY Biotechnology is developing therapeutics that increase healthspan by preventing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related afflictions such as osteoarthritis, atherosclerosis, eye diseases, and kidney disease. Backed by a group of visionary investors, UNITY's world-class management team has experience building companies and developing medicines together: the team has collectively moved more than 90 therapeutic candidates into human clinical trials and developed 13 FDA-approved medicines. UNITY's mission is to build a future in which it doesn't hurt to be old - a future in which people stay healthy and mobile long into old age.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/28/16 | $116,000,000 | Series B |
ARCH Venture Partners Baillie Gifford Fidelity Investments Mayo Clinic Ventures Partner Fund Management Venrock WuXi PharmaTech | undisclosed |
| 08/17/17 | $35,000,000 | Series B |
ARCH Venture Partners Baillie Gifford COM Investments Cycad Group Fidelity Management & Research Company Founders Fund INVUS Opportunities Partner Fund Management Pivotal Alpha Three Lakes Partners Venrock Vulcan Capital | undisclosed |
